Glycation End Products, Advanced
"Glycation End Products, Advanced" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterogeneous group of compounds derived from rearrangements, oxidation, and cross-linking reactions that follow from non-enzymatic glycation of amino groups in proteins. They are also know as Maillard products. Their accumulation in vivo accelerates under hyperglycemic, oxidative, or inflammatory conditions. Heat also accelerates the formation of advanced glycation end products (AGEs) such seen with the browning of food during cooking under or over high heat.
| Descriptor ID |
D017127
|
| MeSH Number(s) |
D12.776.643.500
|
| Concept/Terms |
Glycation End Products, Advanced- Glycation End Products, Advanced
- Maillard Reaction End Products
- Maillard Reaction Products
- Products, Maillard Reaction
- Reaction Products, Maillard
- Advanced Maillard Reaction End Products
- Glycation Endproducts, Advanced
- Endproducts, Advanced Glycation
- Glycosylation End Products, Advanced
- Advanced Glycosylation Endproducts
- Endproducts, Advanced Glycosylation
- Glycosylation Endproducts, Advanced
- Advanced Glycation End Products
- Advanced Glycosylation End Products
- Maillard Products
- Products, Maillard
- Advanced Glycation Endproducts
|
Below are MeSH descriptors whose meaning is more general than "Glycation End Products, Advanced".
Below are MeSH descriptors whose meaning is more specific than "Glycation End Products, Advanced".
This graph shows the total number of publications written about "Glycation End Products, Advanced" by people in this website by year, and whether "Glycation End Products, Advanced" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2012 | 0 | 2 | 2 |
| 2015 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glycation End Products, Advanced" by people in Profiles.
-
Stickle DF, DiNatale GJ, Molinaro R. Minimal mathematical model for glycation of albumin. Clin Biochem. 2024 Dec; 133-134:110830.
-
Bou-Teen D, Fernandez-Sanz C, Miro-Casas E, Nichtova Z, Bonzon-Kulichenko E, Cas?s K, Inserte J, Rodriguez-Sinovas A, Benito B, Sheu SS, V?zquez J, Ferreira-Gonz?lez I, Ruiz-Meana M. Defective dimerization of FoF1-ATP synthase secondary to glycation favors mitochondrial energy deficiency in cardiomyocytes during aging. Aging Cell. 2022 03; 21(3):e13564.
-
Siegman MJ, Eto M, Butler TM. Remodeling of the rat distal colon in diabetes: function and ultrastructure. Am J Physiol Cell Physiol. 2016 Jan 15; 310(2):C151-60.
-
Juraschek SP, Steffes MW, Miller ER, Selvin E. Alternative markers of hyperglycemia and risk of diabetes. Diabetes Care. 2012 Nov; 35(11):2265-70.
-
Vos FE, Schollum JB, Coulter CV, Manning PJ, Duffull SB, Walker RJ. Assessment of markers of glycaemic control in diabetic patients with chronic kidney disease using continuous glucose monitoring. Nephrology (Carlton). 2012 Feb; 17(2):182-8.
-
Wang XL, Lau WB, Yuan YX, Wang YJ, Yi W, Christopher TA, Lopez BL, Liu HR, Ma XL. Methylglyoxal increases cardiomyocyte ischemia-reperfusion injury via glycative inhibition of thioredoxin activity. Am J Physiol Endocrinol Metab. 2010 Aug; 299(2):E207-14.
-
Berrou J, Tostivint I, Verrecchia F, Berthier C, Boulanger E, Mauviel A, Marti HP, Wautier MP, Wautier JL, Rondeau E, Hertig A. Advanced glycation end products regulate extracellular matrix protein and protease expression by human glomerular mesangial cells. Int J Mol Med. 2009 Apr; 23(4):513-20.
-
Ehlermann P, Eggers K, Bierhaus A, Most P, Weichenhan D, Greten J, Nawroth PP, Katus HA, Remppis A. Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products. Cardiovasc Diabetol. 2006 Mar 30; 5:6.
-
Arumugam T, Simeone DM, Van Golen K, Logsdon CD. S100P promotes pancreatic cancer growth, survival, and invasion. Clin Cancer Res. 2005 Aug 01; 11(15):5356-64.
-
Zhang L, Zalewski A, Liu Y, Mazurek T, Cowan S, Martin JL, Hofmann SM, Vlassara H, Shi Y. Diabetes-induced oxidative stress and low-grade inflammation in porcine coronary arteries. Circulation. 2003 Jul 29; 108(4):472-8.